Clinico-Therapeutic Trial of Acyclovir against Canine Parvovirus Infection

The main goal of this study was to investigate the safety and efficacy of acyclovir, as an antiviral agent on the clinical recovery of puppies with acute hemorrhagic diarrhea. The dogs were naturally infected by CPV-2. Out of the total 30 dogs, 20 dogs were naturally infected with CPV-2, and 10 healthy dogs less than 6 months of age were selected. The animals were grouped into 3 groups, each containing 10 puppies. Group A was treated with Acyclovir along with supportive treatment, group B was treated with only supportive treatment, while group C was kept as a negative control group and without treatment. Blood samples and fecal samples were collected before treatment and after treatment from all groups. In parvo-infected dogs, marked hemoconcentration, leucopenia, neutropenia, and alterations in the biochemical profile were noticed as compared to healthy dogs. The Acyclovir along with supportive treatment progressively improved the leukocyte, neutrophil counts over time in parvovirus-infected dogs compared to dogs that received only supportive treatment. Our obtained results show that Acyclovir has the best effect in the prevention of CPV2 replication in puppies through the absence of a clinical sign of CPV-2 and hematological recovery.

Author(s):

Muhammad Waqas, Muhammad Asif Muneer*, Mubashir Farooq, Muhammad Mubeen

Abstract | Full-Text | PDF

Share this